Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 9/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etisazole SCHEMBL30496100 | 1.00 | EPAS1 (0.56) | EPAS1ACHEEPHX2MAPTKDM4E | |
| SCHEMBL13202776 | 0.85 | EPAS1 (0.59) | EPAS1ACHEEPHX2MAPTKDM4E | |
| SCHEMBL3854234 | 0.82 | SMN1; SMN2 (0.51) | EPAS1ACHEUTS2RSMN1; SMN2 | |
| SCHEMBL13202796 | 0.81 | EPAS1 (0.56) | EPAS1ACHEEPHX2MAPTKDM4E | |
| SCHEMBL2977289 | 0.79 | EPAS1 (0.53) | EPAS1ACHEEPHX2MAPTKDM4E | |
| SCHEMBL11443229 | 0.79 | EPAS1 (0.61) | EPAS1ACHEEPHX2MAPTKDM4E | |
| SCHEMBL21336655 | 0.77 | EPAS1 (0.65) | EPAS1ACHEEPHX2MAPTKDM4E | |
| SCHEMBL9066324 | 0.77 | EPAS1 (0.51) | EPAS1ACHEEPHX2MAPTKDM4E | |
| SCHEMBL6108893 | 0.76 | EPAS1 (0.50) | EPAS1ACHEEPHX2MAPTKDM4E | |
| SCHEMBL7378228 | 0.76 | EPAS1 (0.33) | EPAS1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11534375-B2 | Solvent-free method of encapsulating a hydrophobic active | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-12-27 | — | — | US | claimed |
| US-20200179248-A1 | SOLVENT-FREE METHOD OF ENCAPSULATING A HYDROPHOBIC ACTIVE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-06-11 | — | — | US | claimed |
| WO-2018182509-A1 | SOLVENT-FREE METHOD OF ENCAPSULATING A HYDROPHOBIC ACTIVE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-10-04 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| CN-103923765-A | Detergent Composition For Process Of Manufacturing Semiconductors And Displays | COWON INNOTECH INC | 2014-07-16 | — | — | CN | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20030007826-A1 | Adhesive treatment for tinea pedis | CLOSURE MEDICAL CORPORATION | 2003-01-09 | — | — | US | claimed |
| US-20030007947-A1 | Adhesive treatment for oral fungal infection | CLOSURE MEDICAL CORPORATION (US) | 2003-01-09 | — | — | US | claimed |
| US-20030007946-A1 | Adhesive treatment for tinea cruris | CLOSURE MEDICAL CORPORATION (US) | 2003-01-09 | — | — | US | claimed |
| US-20030007948-A1 | Adhesive treatment for skin yeast infections | CLOSURE MEDICAL CORPORATION (US) | 2003-01-09 | — | — | US | claimed |
| US-20030007949-A1 | Adhesive treatment for tinea corporis | CLOSURE MEDICAL CORPORATION (US) | 2003-01-09 | — | — | US | claimed |
| EP-0687172-B1 | SOLID LIPID PARTICLES, PARTICLES OF BIOACTIVE AGENTS AND METHODS FOR THE MANUFACTURE AND USE THEREOF | PHARMACIA AB (SE) | 2002-12-04 | — | — | EP | claimed |
| US-6207178-B1 | STABLE SUSPENSION | KABI PHARMACIA AB (SE) | 2001-03-27 | — | — | US | claimed |
| US-5785976-A | Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof | PHARMACIA & UPJOHN AB (SE) | 1998-07-28 | — | — | US | claimed |
| EP-0687172-A1 | SOLID LIPID PARTICLES, PARTICLES OF BIOACTIVE AGENTS AND METHODS FOR THE MANUFACTURE AND USE THEREOF | Pharmacia & Upjohn Aktiebolag (SE) | 1995-12-20 | — | — | EP | claimed |
| WO-1994020072-A1 | SOLID LIPID PARTICLES, PARTICLES OF BIOACTIVE AGENTS AND METHODS FOR THE MANUFACTURE AND USE THEREOF | PHARMACIA AB (SE) | 1994-09-15 | — | — | WO | claimed |